In This Article:
Bioventus (BVS) announced that it has successfully completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners, a private equity firm focused on acquiring and growing commercial-stage HealthTech companies. The transaction, announced on October 1, 2024, enables Bioventus to continue improving its focus and execution within the Company’s core businesses, while also delivering approximately $20 million of net closing proceeds to enhance liquidity.
Don't Miss Our New Year's Offers:
-
Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
-
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BVS: